NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Tenax Therapeutics, Inc. (TENX) Stock Analysis

Tenax Therapeutics, Inc. (TENX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TENX

$1.94

+$0.16 (+8.99%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TENX with… →

TENX Key Statistics

As of Sep 4, 2026
Trading
Open
$1.82
Previous Close
$1.78
Day's Range
1.80–1.96
52-Week Range
1.31–19.40
Volume
4.41M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.82
Valuation
Market Cap
$72.60M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.44
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.61
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$52.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
37.42M
1-Year Return
−67.67%
Dividend and dates
Avg Volume
4.91M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TENX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−84.09%
2025+96.93%
2024−71.86%
2023−87.61%
2022−89.33%
2021−44.09%
2020+31.91%
2019+16.53%
2018−87.65%
2017−74.87%
2016 (partial year)−21.69%

As of September 4, 2026.

TENX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$52.60M—
2024$0.00−$17.60M—
2023$0.00−$7.71M—
2022$0.00−$11.05M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$56.39M−$52.60M—
2024$0.00—−$19.49M−$17.60M—
2023$0.00—−$8.23M−$7.71M—
2022$0.00—−$11.05M−$11.05M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TENX Valuation vs Biotechnology Median

Median of 656 stocks
MetricTENXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Tenax Therapeutics, Inc. (TENX) at $72.60M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 14.

The 52-week range on file runs from $1.31 to $19.40. TENX last closed at $1.94 on September 4, 2026. That is +$0.16 (+8.99%) against the previous close. The latest close sits 48.09% above that 52-week low.

Financial Health

In fiscal 2025, Tenax Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $52.60M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.61.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.44.

Beta against the wider market is reported at 0.82. Daily returns over the trailing 10 years annualize to a volatility of 147.58%. The trailing one-year price return is −67.67%. Across 10 years the annualized return works out at −65.20%.

Growth & Income

No dividend is on file for TENX.

The strongest complete calendar year on file is 2025 at +96.93%; the weakest is 2022 at −89.33%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is −84.09%.

Peer Comparison

Tenax Therapeutics, Inc. (TENX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tenax Therapeutics, Inc. TENX $72.60M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Tenax Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

Visit website →